Piasky
Piasky ingredients
| Active ingredient | Strength |
|---|---|
| Crovalimab | 340 mg/2mL |
What Piasky is used for
The FDA lists the approved uses on the official label (below). In the EU, crovalimab is approved as Piasky for:
Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): In patients with haemolysis with clinical symptom(s) indicative of high disease activity. In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Piasky
- Generic name
- Crovalimab
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Complement C5 Inhibitor
- FDA approval
- Biologic licence (BLA) BLA761388
- On the US market since
- 2024
Official information
- Piasky prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Crovalimab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Piasky?
Piasky (Crovalimab) is a specialist medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Piasky?
Piasky contains Crovalimab (340 mg/2mL).
Is Piasky approved in Europe?
The same active substance is approved in the EU as Piasky.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA